Imagining a World Without Ads. Reinventing Brand Building with P&G in Latin America.
Meet top emerging MIT-connected startups during this 2-day webinar featuring startups from MIT Startup Exchange’s accelerator program, STEX25. The format is fast-paced, exposing attendees to a broad cross selection of technologies and use cases applicable to many different companies and industries. Sixteen startups will be presenting ‘lightning talks’ followed by Q&A.
Of special note, there will be brief panel discussions on topics related to startup-corporate partnerships. This is a great opportunity for corporate executives and startups alike to learn about challenges that can emerge when the two sides collaborate, and how to create circumstances to improve chances of successful partnerships.
P&G is looking for new approaches and technologies that can help them to address key business challenges/opportunities.
Early-stage startups are invited to MIT.nano to learn more about the START.nano program and explore how its state-of-the-art laboratories can support their growth.
The 2025 MIT Japan Conference will explore future research trends at MIT, highlighting breakthroughs in key areas such as Soft Materials and Mechanics, Biomedical Innovation, and the impact of Generative AI (GAI) on the Work of the Future. Additional sessions will focus on Quantum and Silicon Photonics, Nanotechnology in materials and additive manufacturing, and the latest Machine Learning and AI tools for chemical discovery. Advances in semiconductor technology, hydrogen innovation, and electrochemistry, as well as thermofluidic interfaces, will also be featured.
Please visit the MIT ILP site for the full agenda.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.